New hope for advanced colon cancer: drug combo trial opens
NCT ID NCT07559760
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs for people with advanced colorectal cancer that has stopped responding to initial treatment. About 30 adults aged 18-75 will receive a mix of chemotherapy and targeted therapy. The goal is to see if this approach can delay cancer growth and improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?